GT Biopharma (NASDAQ:GTBP) Trading 6.3% Higher – What’s Next?

GT Biopharma, Inc. (NASDAQ:GTBP) traded up 6.3% on Tuesday . The stock traded as high as $3.14 and last traded at $3.14. 16,681 shares changed hands during trading, a decline of 96% from the average session volume of 402,010 shares. The stock had previously closed at $2.95.

GT Biopharma Trading Down 5.6 %

The company has a 50-day moving average price of $2.53 and a 200-day moving average price of $2.76.

Institutional Trading of GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale acquired a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned about 77.02% of GT Biopharma as of its most recent filing with the Securities & Exchange Commission. 8.15% of the stock is owned by hedge funds and other institutional investors.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.